Delta sleep-inducing peptide (DSIP) Medication Interactions
Share
Delta sleep-inducing peptide (DSIP) interacts with other medications in ways that can influence its known effects on heart rate, heart rate variability (HRV), and electroencephalogram (EEG) patterns.
1. Cardiovascular Interactions: DSIP has been shown to increase heart rate and decrease HRV, indicating a reduction in parasympathetic tone. When used in combination with medications that also affect the autonomic nervous system, such as beta-blockers or anticholinergics, there could be additive or antagonistic effects on heart rate and HRV. For instance, beta-blockers, which decrease heart rate and increase HRV, might counteract the cardiovascular effects of DSIP.[1]
2. EEG and Anesthetic Interactions: DSIP can alter EEG patterns, including reducing delta rhythm and increasing bispectral index (BIS), which indicates a lighter depth of anesthesia. When used with anesthetics like isoflurane, DSIP may reduce the depth of anesthesia, necessitating adjustments in anesthetic dosing to achieve the desired level of sedation. This interaction is particularly relevant in surgical settings where precise control of anesthesia is critical.[1]
3. Antiepileptic Drug Interactions: DSIP has been studied in combination with valproate (VPA), an antiepileptic drug. The combination of DSIP and VPA has been shown to be more effective in reducing seizure activity in animal models than either drug alone. This suggests that DSIP may potentiate the anticonvulsive effects of VPA, potentially allowing for lower doses of VPA to be used, which could reduce the risk of VPA-related side effects.[2-3]
4. Neurochemical Interactions: DSIP can influence neurochemical pathways, including those involving dopamine and serotonin. When combined with medications that affect these neurotransmitter systems, such as antidepressants or antipsychotics, there could be synergistic or antagonistic effects. For example, DSIP's modulation of serotonin levels might enhance the effects of selective serotonin reuptake inhibitors (SSRIs), potentially improving therapeutic outcomes or increasing the risk of serotonin syndrome.[4-5]
5. Ethanol Interaction: DSIP has been shown to interact with ethanol, affecting brain monoamines such as dopamine and serotonin. This interaction could influence the effects of alcohol on the central nervous system, potentially altering the sedative and euphoric effects of ethanol. Clinicians should be cautious when DSIP is used in patients who consume alcohol, as the combined effects could be unpredictable.[5]
In summary, DSIP interacts with other medications in ways that can influence its cardiovascular, EEG, and neurochemical effects. These interactions necessitate careful consideration and monitoring when DSIP is used in combination with other drugs, particularly those affecting the autonomic nervous system, anesthesia, seizure control, and neurotransmitter systems.
1. Delta Sleep-Inducing Peptide Alters Bispectral Index, the Electroencephalogram and Heart Rate Variability When Used as an Adjunct to Isoflurane Anaesthesia.
Pomfrett CJ, Dolling S, Anders NR, et al. European Journal of Anaesthesiology. 2009;26(2):128-34. doi:10.1097/EJA.0b013e32831c8644.
2. Interaction of Delta Sleep-Inducing Peptide and Valproate on Metaphit Audiogenic Seizure Model in Rats. Stanojlović O, Hrncić D, Rasić A, et al. Cellular and Molecular Neurobiology. 2007;27(7):923-32. doi:10.1007/s10571-007-9222-5.
3. Delta-Sleep-Inducing Peptide Potentiates Anticonvulsive Activity of Valproate Against Metaphit-Provoked Audiogenic Seizure in Rats.
Hrncić D, Stanojlović O, Zivanović D, Susić V. Pharmacology. 2006;77(2):78-84. doi:10.1159/000093001.
4. Regulation by Delta-Sleep-Inducing Peptide of the Neurochemical Changes in the Brain Associated With Dopaminergic System Hyperactivity.
Gershtein LM, Dovedova EL. Neurochemical Research. 1999;24(9):1135-41. doi:10.1023/a:1020760303553.
5. Ethanol and Delta-Sleep-Inducing Peptide: Effects on Brain Monoamines.
Yukhananov RY, Tennilä TM, Miroshnicenko TI, et al. Pharmacology, Biochemistry, and Behavior. 1992;43(3):683-7. doi:10.1016/0091-3057(92)90396-w.